SAB Biotherapeutics Secures $175M Oversubscribed Round as Volume Spikes Ahead of Phase 2b Readout
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
SAB Biotherapeutics Inc (NASDAQ: SABS) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida, focused on developing fully human polyclonal antibody therapies. Utilizing its proprietary DiversitAb™ platform and genetically engineered bovine herds, SAB BIO aims to address immune-mediated diseases by targeting underlying causes rather than solely managing symptoms. The company's lead candidate, SAB-142, is designed to delay the progression of type 1 diabetes by preserving insulin-producing beta cells.
| Ticker | Price (USD) | Change (%) | Volume | Avg Volume | Volume Rate | Exchange |
|---|---|---|---|---|---|---|
| SABS | 2.15 | –5.29% | 127,162 | 33,397 | +280.76% | NASDAQ |
Corporate Structure
Founded in 2014 and publicly listed via merger with Big Cypress Acquisition Corp., SAB BIO employs between 51 and 200 professionals across research, development, manufacturing, and corporate functions. Samuel Reich, CEO since 2021, oversees a leadership team experienced in antibody engineering, clinical operations, and strategic finance. The company’s manufacturing footprint includes an 80-acre facility in Lincoln County, South Dakota, designed for housing transchromosomic bovines and scalable antibody production.
Biopharmaceuticals by little plant
Recent Developments
In September 2025, SAB BIO announced an oversubscribed private placement raising USD 175 million to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 type 1 diabetes. On September 2, 2025, the company filed an S-3 registration statement with the SEC to facilitate potential future offerings of common stock. A definitive proxy (DEF 14A) dated August 29, 2025, convened a virtual special meeting of stockholders for September 26, 2025, seeking approval for:
- The issuance of common shares upon conversion of Series B Convertible Preferred Stock, which may exceed 19.99% of outstanding common shares.
- An increase in share authorization under the 2021 Omnibus Equity Incentive Plan from 7,750,000 to 31,932,466.
On LinkedIn, SAB BIO highlighted its involvement in the INNODIA Family & Friends Early-stage T1D Detection Program, which has initiated pilot screening across 10 European sites using ADAP technology and dried blood spot sampling.
Financial and Strategic Analysis
SAB BIO’s share price declined by 5.29% on September 8, 2025, with trading volume nearly four times its 30-day average, indicative of increased investor activity surrounding equity-related filings. The USD 175 million private placement aims to strengthen the balance sheet ahead of anticipated Phase 2b data readouts expected in mid-2026. The upcoming shareholder vote on September 26 may impact equity levels, but it aligns with the company’s objectives to enhance R&D funding and support equity incentives designed to retain scientific talent. Registration under Form S-3 further positions SAB BIO to access public markets efficiently for future capital needs.
Market Position and Industry Context
Operating in the competitive immunotherapy sector, SAB BIO distinguishes itself through its DiversitAb™ platform, which can produce high-potency, fully human polyclonal antibodies at scale without requiring human plasma donors. In addition to type 1 diabetes, the pipeline includes programs focused on organ transplant rejection and influenza, supported by proof-of-concept data from its COVID-19 therapeutic candidate, SAB-185. Partnerships with academic consortia such as INNODIA and government agencies have provided non-dilutive funding and validation of the platform’s capabilities.
tl;dr
As of September 8, 2025, SAB Biotherapeutics (NASDAQ: SABS) trades at USD 2.15, down 5.29%, with volume spiking 280.76% above average. On September 2, the company filed Form S-3 for potential stock offerings and on August 29 announced a September 26 special meeting to obtain shareholder approval for stock issuances related to Series B convertible preferred stock and to increase its equity incentive pool. An oversubscribed USD 175 million private placement will fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 type 1 diabetes, positioning data readouts for mid-2026. Shareholder approvals will influence potential dilution levels and further access to capital for ongoing clinical and platform expansion.